Contezolid

Published

dm+d

Unassigned

New Medicines

Skin and skin structure infections; acute bacterial skin and skin structure infections (ABSSSI)

Information

New molecular entity
Not Known
MicuRx Pharmaceuticals

Development and Regulatory status

None
None
Phase II Clinical Trials

Category

Oxazolidinone - ribosomal protein inhibitors
9 September 2020In England in 2018/19, there were ~241,000 finished consultant episodes of skin infections including cellulitis, local infections of skin tissues and cutaneous abscess. Up to 10% receive targeted antimicrobial therapy based on antibiotic resistance rates (~40 per 100,000 people), rather than empirical therapy. [7]
Skin and skin structure infections; acute bacterial skin and skin structure infections (ABSSSI)
Oral

Trial or other data